Semiallogenic fusions of MSI+ tumor cells and activated B cells induce MSI-specific T cell responses

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Garbe, Yvette ^a,b   Klier, Ulrike ^c   Linnebacher, Michael ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cell fusion; Frameshift antigens; Microsatellite instability; T cell epitopes

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL CLONE; CELL FUSION; CELL GROWTH; CELL SELECTION; CELL STIMULATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PHENOTYPE; TUMOR CELL; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CARCINOMA; CELL STRAIN HCT116; CYTOTOXICITY; GENETICS; HYBRID CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CARCINOMA; CELL FUSION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HCT116 CELLS; HUMANS; HYBRID CELLS; LYMPHOCYTE ACTIVATION; MICROSATELLITE INSTABILITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 80053366771     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-410     Document Type: Article

References (30)

1. Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol 2010, 2010:170432. 2901607, 20631828.
2. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001, 91(12):2417-22. 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U, 11413533.
3. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macrì E, Fornasarig M, Boiocchi M. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999, 154(6):1805-13. 10.1016/S0002-9440(10)65436-3, 1866613, 10362805.
4. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001, 93(1):6-11. 10.1002/ijc.1298, 11391614.
5. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001, 98(23):13255-60. 10.1073/pnas.231326898, 60857, 11687624.
6. Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother 2001, 50(9):469-76. 10.1007/s002620100222, 11761441.
7. Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunl 2003, 23(5):415-23.
8. Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 2004, 25(4):14.
9. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008, 134(4):988-97. 10.1053/j.gastro.2008.01.015, 18395080.
10. Linnebacher M, Wienck A, Boeck I, Klar E. Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol 2010, 2010:841451. 2842904, 20339516.
11. Walden P. Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol 2000, 465:347-54.
12. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005, 11(21):7891-900. 10.1158/1078-0432.CCR-05-1330, 16278414.
13. Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y, Zhang X, Ma B, Fan Q. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007, 105(3):277-86. 10.1007/s10549-006-9457-8, 17187233.
14. Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, Koski GK, Shu S. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 2008, 127(1):66-77. 10.1016/j.clim.2007.12.001, 18262845.
15. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007, O30(7):749-61.
16. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparbier K, Sterry W, Walden P. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 2005, 23(17-18):2367-73. 10.1016/j.vaccine.2005.01.081, 15755630.
17. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004, 27(6):452-9. 10.1097/00002371-200411000-00005, 15534489.
18. Schultze JL, Grabbe S, von Bergwelt-Baildon MS. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 2004, 25(12):659-64. 10.1016/j.it.2004.09.016, 15530836.
19. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003, 63(11):2836-43.
20. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99(9):3319-25. 10.1182/blood.V99.9.3319, 11964299.
21. Klier U, Maletzki C, Klar E, Linnebacher M. Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg 2010, 395(4):365-71. 10.1007/s00423-010-0598-1, 20309577.
22. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997, 100(11):2757-65. 10.1172/JCI119822, 508480, 9389740.
23. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 2010, (38 Database):D682-9.
24. Brossart P, Bevan MJ. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996, 183(6):2449-58. 10.1084/jem.183.6.2449, 2192615, 8676065.
25. Dunnion DJ, Cywinski AL, Tucker VC, Murray AK, Rickinson AB, Coulie P, Browning MJ. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999, 98(4):541-50. 10.1046/j.1365-2567.1999.00912.x, 2326964, 10594686.
26. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, Jakubchak S, Bouton-Verville H, Williamson J, Meyer K, Evans L, Martin J, Stephenson JJ, Trocha S, Smith S, Wagner TE. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol Rep 2007, 18(3):665-71.
27. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003, 225(2):65-74. 10.1016/j.cellimm.2003.09.005, 14698141.
28. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003, 170(10):5317-25. 2553207, 12734382.
29. Koido S, Tanaka Y, Tajiri H, Gong J. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 2007, 25(14):2610-9. 10.1016/j.vaccine.2006.12.035, 2073001, 17239504.
30. Cywinski AL, Dunnion DJ, Teobald I, Tucker VC, Browning MJ. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro. Tissue Antigens 2006, 68(2):115-26. 10.1111/j.1399-0039.2006.00623.x, 16866881.